FS Development Corp. II
Completed
Follow
Detailed Information
Information on this SPAC.
- Sponsors
- IPO Size
- $150M
- Underwriters
- Focus
- Healthcare, Biotech, Life Sciences
- SEC Filings
- 1822711
- Public Embarc Page
- https://embarc.com/capital/spac/1822711/FSII/fs-development
- IPO Ticker
- FSII
SPAC Leadership
Information on the SPAC leadership.
- President, Chief Executive Officer and DirectorJim Tananbaum
- Chief Financial OfficerDennis Ryan
- Vice President and DirectorMichael Rome
- DirectorDaniel Dubin
- DirectorOwen Hughes
- DirectorDeepa Pakianathan
- President, Chief Executive Officer and DirectorDr. Jim Tananbaum(Founder, Foresite Capital)
- DirectorAlisa Mall
Target Information
Information on the SPAC target for merger.
- Company
- Pardes Biosciences
- Presentation
- Investor Presentation (SEC) on 2021-12-21
- New Ticker
- PRDS
- Description
- Pardes is developing an "oral antiviral drug candidate to treat and prevent SARS-CoV-2 infections as well as additional candidates from the company's tunable, reversible covalent chemistry platform."